

CITATION REPORT

List of articles citing

Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice

DOI: 10.1016/j.nmd.2006.06.011

Neuromuscular Disorders, 2006, 16, 591-602.

Source: <https://exaly.com/paper-pdf/39937167/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
183	uPA deficiency exacerbates muscular dystrophy in MDX mice. 2007 , 178, 1039-51		57
182	Bibliography. Current world literature. Neuro-muscular diseases: nerve. 2007 , 20, 600-4		
181	Effects of inhibitors of the arachidonic acid cascade on primary muscle culture from a Duchenne muscular dystrophy patient. 2007 , 77, 217-23		9
180	Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. <i>Neuromuscular Disorders</i> , 2007 , 17, 376-84	2.9	22
179	Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. 2007 , 39, 469-77		68
178	Novel activity of an anti-inflammatory cytokine: IL-10 prevents TNF α -induced resistance to IGF-I in myoblasts. 2007 , 188, 48-55		29
177	Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. 2008 , 37, 61-7		15
176	N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. 2008 , 586, 2003-14		177
175	Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. 2008 , 35, 846-51		66
174	Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. 2008 , 252, 91-110		169
173	Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. 2008 , 31, 1-19		245
172	Tumor necrosis factor- α inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. 2008 , 26, 997-1008		61
171	Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. <i>Neuromuscular Disorders</i> , 2008 , 18, 227-38	2.9	68
170	L-arginine decreases inflammation and modulates the nuclear factor- κ B/matrix metalloproteinase cascade in mdx muscle fibers. <i>American Journal of Pathology</i> , 2008 , 172, 1509-19	5.8	126
169	Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. <i>Human Molecular Genetics</i> , 2008 , 17, 2280-92	5.6	64
168	Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice. 2008 , 30, 160-9		25
167	Steroid treatment causes deterioration of myocardial function in the Δ -sarcoglycan-deficient mouse model for dilated cardiomyopathy. 2008 , 79, 652-61		29

166	Three-dimensional optical coherence tomography of whole-muscle autografts as a precursor to morphological assessment of muscular dystrophy in mice. 2008 , 13, 011003		9
165	Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. <i>Human Molecular Genetics</i> , 2009 , 18, 482-96	5.6	337
164	Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. 2009 , 119, 1583-94		199
163	Muscle degeneration and leukocyte infiltration caused by mutation of zebrafish Fad24. 2009 , 238, 86-99		22
162	Sarcoplasmic-endoplasmic-reticulum Ca ²⁺ -ATPase and calsequestrin are overexpressed in spared intrinsic laryngeal muscles of dystrophin-deficient mdx mice. 2009 , 39, 609-15		27
161	The physiological effects of IGF-1 (class 1:Ea transgene) over-expression on exercise-induced damage and adaptation in dystrophic muscles of mdx mice. 2009 , 457, 1121-32		9
160	Body composition and muscular strength changes after moderate activity: association with matrix metalloproteinase polymorphisms. 2009 , 49 Suppl 1, 83-94		6
159	Nitric oxide and repair of skeletal muscle injury. 2009 , 21, 157-63		94
158	Mammalian animal models for Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2009 , 19, 241-9	2.9	139
157	Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. 2009 , 1, 755-68		69
156	Imatinib attenuates skeletal muscle dystrophy in mdx mice. 2009 , 23, 2539-48		80
155	Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. 2009 , 220, 349-58		53
154	Recombinant human soluble tumor necrosis factor-alpha receptor fusion protein partly attenuates ventilator-induced lung injury. 2009 , 31, 262-6		30
153	Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. 2009 , 88, 502-22		61
152	Clinical use of immunosuppressants in Duchenne muscular dystrophy. 2010 , 12, 1-21		7
151	Use of pifithrin to inhibit p53-mediated signalling of TNF in dystrophic muscles of mdx mice. 2010 , 337, 119-31		11
150	Nicotinic acetylcholine receptor activation reduces skeletal muscle inflammation of mdx mice. 2010 , 227, 44-51		25
149	Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. 2010 , 10, 363		112

148	The chondrogenic response to exercise in the proximal femur of normal and mdx mice. 2010 , 11, 198		1
147	Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. 2010 , 29, 391-8		49
146	Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. 2010 , 260, 75-82		124
145	Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice. 2010 , 41, 487-99		31
144	Timeline of cardiac dystrophy in 3-18-month-old MDX mice. 2010 , 42, 504-13		40
143	Soluble TNF- α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer. 2010 , 17, 1400-10		5
142	Regulatory interactions between muscle and the immune system during muscle regeneration. 2010 , 298, R1173-87		704
141	Targeting fibrosis in Duchenne muscular dystrophy. 2010 , 69, 771-6		102
140	Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate. <i>Neuromuscular Disorders</i> , 2010 , 20, 267-72		13
139	Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. 2010 , 21, 221-37		32
138	Emerging drugs for treating skeletal muscle injury and promoting muscle repair. 2011 , 16, 163-82		13
137	Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. <i>Neuromuscular Disorders</i> , 2011 , 21, 132-41	2.9	31
136	Eicosapentaenoic acid decreases TNF- α and protects dystrophic muscles of mdx mice from degeneration. 2011 , 232, 145-50		35
135	Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice. 2011 , 90, 264-70		14
134	The role of nitric oxide during healing of trauma to the skeletal muscle. 2011 , 60, 347-56		28
133	Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. <i>Human Molecular Genetics</i> , 2011 , 20, 790-805	5.6	203
132	Identification of muscle necrosis in the mdx mouse model of Duchenne muscular dystrophy using three-dimensional optical coherence tomography. 2011 , 16, 076013		21
131	Glucocorticoid analogues: potential therapeutic alternatives for treating inflammatory muscle diseases. 2012 , 12, 95-103		14

130	Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the $\alpha_5\beta_1$ leukocyte integrin receptor. <i>Human Molecular Genetics</i> , 2012 , 21, 1989-2004	5.6	32
129	Emerging drugs for Duchenne muscular dystrophy. 2012 , 17, 261-77		79
128	Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. <i>DMM Disease Models and Mechanisms</i> , 2013 , 6, 197-205	4.1	41
127	Proinflammatory macrophages enhance the regenerative capacity of human myoblasts by modifying their kinetics of proliferation and differentiation. 2012 , 20, 2168-79		97
126	Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. 2012 , 46, 917-25		31
125	Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance. <i>Neuromuscular Disorders</i> , 2012 , 22, 122-8	2.9	12
124	A single 30 min treadmill exercise session is suitable for proof-of concept studies in adult mdx mice: a comparison of the early consequences of two different treadmill protocols. <i>Neuromuscular Disorders</i> , 2012 , 22, 170-82	2.9	48
123	IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. 2012 , 13, 106		26
122	TNFR1-dependent pulmonary apoptosis during ischemic acute kidney injury. 2012 , 303, L449-59		24
121	Accelerated skeletal muscle recovery after in vivo polyphenol administration. 2012 , 23, 1072-9		34
120	Immunological Components of Genetically Inherited Muscular Dystrophies: Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy Type 2B. 2012 , 1065-1075		
119	PKC theta ablation improves healing in a mouse model of muscular dystrophy. <i>PLoS ONE</i> , 2012 , 7, e31515.7	3.7	36
118	Fatty acid profile of skeletal muscle phospholipid is altered in mdx mice and is predictive of disease markers. 2012 , 61, 801-11		22
117	Ascorbic acid protects the diaphragm muscle against myonecrosis in mdx mice. 2012 , 28, 686-90		22
116	An anti-inflammatory role for leukemia inhibitory factor receptor signaling in regenerating skeletal muscle. 2013 , 139, 13-34		32
115	Wasting mechanisms in muscular dystrophy. 2013 , 45, 2266-79		91
114	The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. <i>European Journal of Pharmacology</i> , 2013 , 715, 296-303	5.3	16
113	Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy. <i>Journal of Muscle Research and Cell Motility</i> , 2013 , 34, 1-13	3.5	56

112	EPA protects against muscle damage in the mdx mouse model of Duchenne muscular dystrophy by promoting a shift from the M1 to M2 macrophage phenotype. 2013 , 264, 41-7		33
111	Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy. 2013 , 2013, 540370		74
110	Reining in nuclear factor-kappaB in skeletal muscle disorders. 2013 , 16, 251-7		5
109	Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. 2013 , 210, 2223-37		97
108	The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. <i>Journal of Pathology</i> , 2013 , 231, 199-209	9.4	18
107	Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. <i>Scientific Reports</i> , 2013 , 3, 2183	4.9	20
106	The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. <i>PLoS ONE</i> , 2013 , 8, e77745	3.7	13
105	Influence of immune responses in gene/stem cell therapies for muscular dystrophies. 2014 , 2014, 818107		6
104	Anti-inflammatory cytokine therapy in dystrophinopathies. 2014 , 5, 288-289		
103	Advancements in stem cells treatment of skeletal muscle wasting. <i>Frontiers in Physiology</i> , 2014 , 5, 48	4.6	15
102	Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. 2014 , 2014, 949730		13
101	From innate to adaptive immune response in muscular dystrophies and skeletal muscle regeneration: the role of lymphocytes. 2014 , 2014, 438675		39
100	Macrophage plasticity in skeletal muscle repair. 2014 , 2014, 560629		112
99	Milk-derived ribonuclease 5 preparations induce myogenic differentiation in vitro and muscle growth in vivo. 2014 , 97, 7325-33		5
98	Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse. 2014 , 50, 283-6		4
97	Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. 2014 , 6, 258ra142		145
96	Early inhibition of tumor necrosis factor- α and interleukin-6 in muscle tissue as a therapy for dystrophinopathy in mdx mice. 2014 , 5, 371-377		1
95	Etanercept reduces neuroinflammation and lethality in mouse model of Japanese encephalitis. 2014 , 210, 875-89		48

94	Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. <i>Human Molecular Genetics</i> , 2014 , 23, 3990-4000	5.6	28
93	The need to more precisely define aspects of skeletal muscle regeneration. 2014 , 56, 56-65		35
92	Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. <i>Neuromuscular Disorders</i> , 2014 , 24, 583-95	2.9	36
91	Shared signaling systems in myeloid cell-mediated muscle regeneration. 2014 , 141, 1184-96		93
90	High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics. 2014 , 3, 752-80		11
89	Reduction in mdx mouse muscle degeneration by low-intensity endurance exercise: a proteomic analysis in quadriceps muscle of exercised compared with sedentary mdx mice. 2015 , 35,		13
88	Expression of intercellular adhesion molecule-1 by myofibers in mdx mice. 2015 , 52, 795-802		5
87	Changes in calsequestrin, TNF- α and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles. 2015 , 96, 285-93		12
86	Low-Level Laser Therapy (LLLT) in Dystrophin-Deficient Muscle Cells: Effects on Regeneration Capacity, Inflammation Response and Oxidative Stress. <i>PLoS ONE</i> , 2015 , 10, e0128567	3.7	20
85	Improvement of endurance of DMD animal model using natural polyphenols. 2015 , 2015, 680615		7
84	Role of Inflammation in Muscle Homeostasis and Myogenesis. 2015 , 2015, 805172		137
83	Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. <i>Nature Medicine</i> , 2015 , 21, 786-94	50.5	358
82	Roles of ADAM8 in elimination of injured muscle fibers prior to skeletal muscle regeneration. <i>Mechanisms of Development</i> , 2015 , 135, 58-67	1.7	16
81	The immune system in Duchenne muscular dystrophy: Friend or foe. <i>Rare Diseases (Austin, Tex)</i> , 2015 , 3, e1010966		42
80	Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells. <i>Redox Report</i> , 2015 , 20, 109-15	5.9	11
79	Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015 , 1852, 2170-82	6.9	14
78	Enhancement of Muscle T Regulatory Cells and Improvement of Muscular Dystrophic Process in mdx Mice by Blockade of Extracellular ATP/P2X Axis. <i>American Journal of Pathology</i> , 2015 , 185, 3349-60	5.8	26
77	Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2016 , 6, 37-48	5.4	13

76	Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2745-58	4.4	39
75	Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation. <i>Scientific Reports</i> , 2016 , 6, 24708	4.9	24
74	Degenerative and regenerative features of myofibers differ among skeletal muscles in a murine model of muscular dystrophy. <i>Journal of Muscle Research and Cell Motility</i> , 2016 , 37, 153-164	3.5	5
73	Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy. <i>Human Molecular Genetics</i> , 2016 , 25, 5167-5177	5.6	11
72	[Inflammation and muscle regeneration, a double-edged sword]. <i>Medecine/Sciences</i> , 2016 , 32, 591-7		5
71	Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles. <i>Journal of Neuromuscular Diseases</i> , 2016 , 3, 455-473	5	56
70	Inflammatory predisposition predicts disease phenotypes in muscular dystrophy. <i>Inflammation and Regeneration</i> , 2016 , 36, 14	10.9	19
69	Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca ²⁺ , Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. <i>Physiological Reviews</i> , 2016 , 96, 253-305	47.9	217
68	Histopathological and ultra-structural characterization of local neuromuscular damage induced by repeated phosphatidylcholine/deoxycholate injection. <i>Experimental and Toxicologic Pathology</i> , 2016 , 68, 39-46		4
67	Stem Cell Therapy in Muscle Degeneration. 2017 , 55-91		
66	Low-Intensity Training and the C5a Complement Antagonist NOX-D21 Rescue the mdx Phenotype through Modulation of Inflammation. <i>American Journal of Pathology</i> , 2017 , 187, 1147-1161	5.8	13
65	The Matrix Metalloproteinase and Tissue Inhibitors of Metalloproteinase Balance in Physiological and Pathological Remodeling of Skeletal Muscles. 2017 , 49-76		0
64	Connexins and Pannexins in Bone and Skeletal Muscle. <i>Current Osteoporosis Reports</i> , 2017 , 15, 326-334	5.4	22
63	Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 27	7.3	20
62	Targeting early PKC-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy. <i>Journal of Pathology</i> , 2018 , 244, 323-333	9.4	9
61	Immunobiology of Inherited Muscular Dystrophies. <i>Comprehensive Physiology</i> , 2018 , 8, 1313-1356	7.7	39
60	Sex influences diaphragm muscle response in exercised mdx mice. <i>Cell Biology International</i> , 2018 , 42, 1611-1621	4.5	3
59	Necroptosis mediates myofibre death in dystrophin-deficient mice. <i>Nature Communications</i> , 2018 , 9, 3655	17.4	34

58	The Muscle Stem Cell Niche in Health and Disease. <i>Current Topics in Developmental Biology</i> , 2018 , 126, 23-65	5.3	51
57	Macrophages Are Key Regulators of Stem Cells during Skeletal Muscle Regeneration and Diseases. <i>Stem Cells International</i> , 2019 , 2019, 4761427	5	63
56	Fibro-Adipogenic Progenitors Cross-Talk in Skeletal Muscle: The Social Network. <i>Frontiers in Physiology</i> , 2019 , 10, 1074	4.6	71
55	Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy. <i>Nature Communications</i> , 2019 , 10, 2788	17.4	9
54	Dystrophin deficiency promotes leukocyte recruitment in mdx mice. <i>Pediatric Research</i> , 2019 , 86, 188-194	4.2	4
53	Normal inflammation and regeneration of muscle following injury require osteopontin from both muscle and non-muscle cells. <i>Skeletal Muscle</i> , 2019 , 9, 6	5.1	10
52	P2X7 purinoceptor as a therapeutic target in muscular dystrophies. <i>Current Opinion in Pharmacology</i> , 2019 , 47, 40-45	5.1	11
51	Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage. <i>Cell</i> , 2019 , 177, 541-555.e17	56.2	144
50	Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids. <i>Calcified Tissue International</i> , 2019 , 104, 182-192	3.9	2
49	Effects of chronic treatment with gold nanoparticles on inflammatory responses and oxidative stress in Mdx mice. <i>Journal of Drug Targeting</i> , 2020 , 28, 46-54	5.4	11
48	Comparative study between human mesenchymal stem cells and etanercept as immunomodulatory agents in rat model of rheumatoid arthritis. <i>Immunologic Research</i> , 2020 , 68, 255-268	4.3	8
47	Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application. <i>Expert Review of Proteomics</i> , 2020 , 17, 365-375	4.2	4
46	Accelerated Muscle Recovery After In Vivo Curcumin Supplementation. <i>Natural Product Communications</i> , 2020 , 15, 1934578X2090189	0.9	1
45	Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. <i>DMM Disease Models and Mechanisms</i> , 2020 , 13,	4.1	33
44	Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy. <i>Stem Cell Research and Therapy</i> , 2021 , 12, 78	8.3	3
43	The linkage between inflammation and fibrosis in muscular dystrophies: The axis autotaxin-lysophosphatidic acid as a new therapeutic target?. <i>Journal of Cell Communication and Signaling</i> , 2021 , 15, 317-334	5.2	5
42	The Role of Innate and Adaptive Immune Cells in Skeletal Muscle Regeneration. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
41	Early Inflammation in Muscular Dystrophy Differs between Limb and Respiratory Muscles and Increases with Dystrophic Severity. <i>American Journal of Pathology</i> , 2021 , 191, 730-747	5.8	3

40	Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
39	Histological Analysis of Tibialis Anterior Muscle of DMDmdx4Cv Mice from 1 to 24 Months. <i>Journal of Neuromuscular Diseases</i> , 2021 , 8, 513-524	5	1
38	Myeloid cell-mediated targeting of LIF to dystrophic muscle causes transient increases in muscle fiber lesions by disrupting the recruitment and dispersion of macrophages in muscle. <i>Human Molecular Genetics</i> , 2021 ,	5.6	0
37	Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration. <i>Biomedicines</i> , 2021 , 9,	4.8	3
36	Therapeutic approaches for the sarcomeric protein diseases. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 642, 207-23	3.6	1
35	Inflammation in Skeletal Muscle Regeneration. 2008 , 243-268		13
34	Complexity of Extracellular Matrix and Skeletal Muscle Regeneration. 2008 , 269-302		21
33	Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. <i>JCI Insight</i> , 2018 , 3,	9.9	57
32	The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice. <i>PLOS Currents</i> , 2011 , 3, RRN1276		14
31	Alterations in the expression of leukemia inhibitory factor following exercise: comparisons between wild-type and mdx muscles. <i>PLOS Currents</i> , 2011 , 3, RRN1277		14
30	Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor. <i>PLoS ONE</i> , 2009 , 4, e5570	3.7	32
29	The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice. <i>PLoS ONE</i> , 2013 , 8, e66617	3.7	3
28	Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein. <i>PLoS ONE</i> , 2017 , 12, e0182449	3.7	9
27	Pharmacological blockade of TNF β prevents sarcopenia and prolongs survival in aging mice. <i>Aging</i> , 2020 , 12, 23497-23508	5.6	6
26	The Immune System in Duchenne Muscular Dystrophy Pathogenesis. <i>Biomedicines</i> , 2021 , 9,	4.8	1
25	Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy. <i>European Journal of Pharmacology</i> , 2021 , 912, 174568	5.3	0
24	Combinatorial Gene Therapy Strategies for Treating Muscular Dystrophies. 2010 , 117-139		
23	Green Tea Polyphenols Improve Bone and Muscle Quality. 2013 , 205-222		1

22	Cell therapeutic approaches using multipotent mesenchymal stromal cells for muscular dystrophy. <i>Inflammation and Regeneration</i> , 2014 , 34, 198-205	10.9	0
21	Low dose resveratrol promotes hypertrophy in wildtype skeletal muscle and reduces damage in skeletal muscle of exercised mdx mice.		
20	Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy. <i>Nature Communications</i> , 2021 , 12, 6264	17.4	4
19	Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. <i>Acta Myologica</i> , 2011 , 30, 16-23	1.6	51
18	Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. <i>Acta Myologica</i> , 2012 , 31, 40-7	1.6	38
17	Effect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism. <i>American Journal of Translational Research (discontinued)</i> , 2020 , 12, 4488-4497	3	1
16	Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathways.. <i>Stem Cell Research and Therapy</i> , 2022 , 13, 7	8.3	
15	P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	2
14	Inhibition of PKC β Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
13	Description of Osmolyte Pathways in Maturing Mice Reveals Altered Levels of Taurine and Sodium/Myo-Inositol Co-Transporters.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
12	Antioxidant effects of bis-indole alkaloid indigo and related signaling pathways in the experimental model of Duchenne muscular dystrophy. <i>Cell Stress and Chaperones</i> ,	4	0
11	Molecular feature of neutrophils in immune microenvironment of muscle atrophy.		0
10	The potential for Treg-enhancing therapies in tissue, in particular skeletal muscle, regeneration.		
9	Cathelicidin-related antimicrobial peptide mediates skeletal muscle degeneration caused by injury and Duchenne muscular dystrophy in mice.		1
8	The inflammatory response, a mixed blessing for muscle homeostasis and plasticity. 13,		0
7	Histological Methods to Assess Skeletal Muscle Degeneration and Regeneration in Duchenne Muscular Dystrophy. 2022 , 23, 16080		0
6	Serum inflammatory cytokines as disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy. 2022 , 15,		1
5	CONVENTIONAL APPROACHES TO THE THERAPY OF HEREDITARY MYOPATHIES. 2022 , 10, 416-431		0

- 4 Protection of dystrophic muscle cells using Idebenone correlates with the interplay between calcium, oxidative stress and inflammation. ○
- 3 Nano-Immunomodulation: A New Strategy for Skeletal Muscle Diseases and Aging?. **2023**, 24, 1175 ○
- 2 Mechanisms of Myofibre Death in Muscular Dystrophies: The Emergence of the Regulated Forms of Necrosis in Myology. **2023**, 24, 362 1
- 1 The Bi-directional Relationship Between Sleep and Inflammation in Muscular Dystrophies: A Narrative Review. **2023**, 105116 ○